Monitor Q1 FY2027 results for continued sequential growth and margin expansion. The company's ability to sustain adjusted EBITDA profitability and execute on its $75M capex plan will be key. AI drug discovery revenue assumption of $100M in FY2027 guidance is a new growth vector to track.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $114.22entry
- T+1 · 4d ago −2.29%α −1.93% · $111.60
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Twist Bioscience reported fiscal Q4 2026 revenue of $126.6M (+28% YoY), above the $123.6M consensus, and achieved positive adjusted EBITDA of $2.2M for the first time. The company guided FY2027 revenue to $550M-$560M (21% YoY growth at the midpoint) and expects continued adjusted EBITDA profitability. Net loss narrowed to $20.6M from $27.1M a year ago.
Key Financial Metrics
Key Facts
- Q4 FY2026 revenue $126.6M, up 28% YoY from $99.0M, above consensus of $123.6M
- Full year FY2026 revenue $459.4M, up 22% YoY from $376.6M
- Q4 adjusted EBITDA positive at $2.2M vs $(7.8M) a year ago, achieving breakeven milestone
- FY2027 revenue guidance $550M-$560M, 21% YoY growth at midpoint
- Q1 FY2027 revenue guidance $130M-$132M, 26% YoY growth at midpoint
- Gross margin expanded to 53.1% in Q4 from 51.3% a year ago
- Cash position strengthened to ~$582M after raising ~$425M in equity offering
- DSPS segment grew 33% YoY to $61.0M; NGS segment grew 24% YoY to $65.7M in Q4
Financial Impact
Revenue beat consensus by ~$3M (2.4%); positive adjusted EBITDA milestone achieved; FY2027 guidance implies 21% revenue growth
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| DNA Synthesis and Protein Solutions (DSPS) | $61.0M | +33.0% |
| NGS Applications (NGS) | $65.7M | +24.0% |
Risk Factors
- Net loss widened to $130.2M for FY2026 from $77.7M in FY2025, driven by higher SG&A expenses
- Selling, general and administrative expenses grew 22% YoY to $301.2M, outpacing revenue growth
- Guidance assumes $100M in AI drug discovery revenue, a new and unproven segment
- Capital expenditures of ~$75M planned for FY2027 may pressure cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001581280-26-000053 |
| Document: twist-20261112.htm | 0001581280-26-000053 |
| Document: 0001581280-26-000053-index-headers.html | 0001581280-26-000053 |
| Document: 0001581280-26-000053-index.html | 0001581280-26-000053 |
| Document: 0001581280-26-000053.txt | 0001581280-26-000053 |
| 8-K Data (Synthetic) | 0001581280-26-000053 |
Track record
47 reports on TWST
8 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +55.24% at T+60 after the Aug 3, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $105.03 Now $105.04 +0.01% settles Dec 15
- Nov 16, 2026today 144 Neutral 2/10 Entry $105.16 Now $105.04 −0.11% settles Dec 15
- Nov 16, 2026today 144 Neutral 2/10 Entry $104.98 Now $105.04 +0.06% settles Dec 15
- Nov 16, 2026today 144 Neutral 2/10 Entry $105.61 Now $105.04 −0.54% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $104.03 Now $105.04 +0.98% settles Dec 15
- Nov 12, 20264d ago 8-K Bullish 6/10 Viewing Entry $114.22 Now $105.04 −8.04% settles Dec 11
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $114.22 Now $105.04 −8.04% settles Dec 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $132.13 Now $105.04 −20.50% settles Dec 9
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $120.79 Now $105.04 −13.04% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $120.61 Now $105.04 −12.91% settles Dec 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers